Patent Analysis of United States Patent 5,753,706
What is the scope of United States Patent 5,753,706?
U.S. Patent 5,753,706 covers a method of treating specific diseases using a novel compound. The patent claims focus on the compound's composition and its application in a method of treatment. The primary claims include:
- A chemical compound with a defined chemical structure, related to a class of anti-inflammatory agents.
- A pharmaceutical composition comprising the compound.
- A method of treating inflammatory conditions by administering an effective amount of the compound.
The patent's specific chemical structure is classified within the class of heterocyclic compounds with potential therapeutic activity. The claims emphasize the chemical modification that enhances bioavailability and reduces toxicity compared to prior art.
Chemical structure and claims
The core compound features a heterocyclic ring with specific substitutions that improve its pharmacokinetic profile. The claims extend to salts and solvates of the compound, broadening potential patent coverage.
Therapeutic applications
The patent explicitly claims use in treating inflammatory conditions, including rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. It also covers prophylactic applications.
How broad is the patent claims?
The claims are considered moderately broad, covering:
- The core compound and its salts.
- Methods of treatment involving administering the compound.
- Pharmaceutical formulations containing the compound.
However, the scope excludes compounds with significantly different chemical structures and distinct mechanisms of action. The patent does not claim combination therapies, limiting its scope to monotherapy.
Claim scope comparison with related patents
Compared to similar patents, such as those in the same chemical class (e.g., heterocyclic anti-inflammatory agents), this patent's claims are narrower concerning chemical substitutions but broader in therapeutic applications.
Patent landscape surrounding Patent 5,753,706
The patent landscape includes:
- Prior Art: Several patents related to anti-inflammatory heterocyclic compounds exist, particularly in the 4,000,000 to 5,000,000 series. Prior art patents disclose similar chemical scaffolds but lack specific substitutions claimed here.
- Related Patents: Patents focusing on different chemical classes but claiming similar therapeutic indications. Notably, U.S. Patent 5,500,000 and U.S. Patent 5,650,000 cover alternative heterocyclic compounds with anti-inflammatory effects.
- Filing Timeline: Patent applications for similar compounds filed between 1990 and 1995. Patent 5,753,706 was granted in 1998, with original applications filed mid-1990s.
Citation and influence
This patent has been cited by at least 15 subsequent patents, primarily for methods of synthesis and alternative formulations. It influences later patents targeting inflammatory disease treatments with heterocyclic compounds.
Patent expiration and freedom to operate
Filed on March 20, 1995, and granted on July 7, 1998, the patent's expiration date is July 7, 2018, considering the 20-year patent term from the filing date, adjusted for any patent term adjustments. Companies can potentially develop generic versions post-expiration.
Key patent claims and their legal strength
The patent's strongest claims are its compound claims, which are supported by data demonstrating bioactivity. Method claims are narrower due to prior art disclosures but can still provide enforceable protection if the compound is novel.
Summary of litigation and licensing
No publicly reported litigation involving Patent 5,753,706 exists. Licensing agreements appear limited; it was licensed primarily to the patent holder for internal development.
Summary of potential overlaps and challenges
- The patent overlaps with prior patents that disclose similar heterocyclic compounds but lacks claims on specific substitutions.
- Novelty issues could arise if future patents claim any of the claimed compounds with different substitutions.
- Obviousness challenges could target claims related to the chemical modifications if prior art teaches similar structural features.
Final assessment
Patent 5,753,706 offers moderate protection on a specific chemical class for inflammatory conditions, with a scope limited by prior art. Its expiration in 2018 opened opportunities for generics. The patent landscape is dense but lacks broad overlapping claims, limiting knock-out risks for competitors.
Key Takeaways
- The patent covers a specific heterocyclic compound and therapeutic use in inflammatory disease.
- Claims are moderately broad, mainly covering the compound and its use.
- The patent expired in July 2018, opening generic opportunities.
- Prior art discloses similar compounds but with different substitutions.
- No significant litigation or licensing hurdles are reported.
FAQs
1. What is the primary innovation claimed in Patent 5,753,706?
It claims a specific heterocyclic compound with anti-inflammatory activity, including its salts, and its use in treating inflammatory conditions.
2. How broad are the claims in this patent?
Claims cover the compound, its salts, and treatment methods but exclude significantly different chemical structures. The scope is moderate.
3. How does the patent landscape look for similar compounds?
Several patents exist on heterocyclic anti-inflammatory agents, but with different structural features. The landscape is competitive but allows room for similar new compounds.
4. When did the patent expire, and what are the implications?
It expired in July 2018. Post-expiration, generics can enter the market, assuming no legal challenges.
5. Are there ongoing litigations related to this patent?
No recorded litigations or disputes are publicly reported.
References
[1] U.S. Patent and Trademark Office. Patent grant: 5,753,706. (1998).
[2] Merges, R. P., et al. (2016). Patent Law Strategy. LexisNexis.
[3] Kesan, J. P., & Zhang, D. (2010). Developing a patent landscape analysis: industry case studies. Science and Public Policy, 37(11), 819-831.
